世界の糖尿病性足潰瘍生物製剤の市場規模は、2024年に20億1000万ドルと推定され、2025年から2030年にかけて7.9%のCAGRで成長すると予測されます。糖尿病性足潰瘍の生物学的製剤製品の需要は、糖尿病性足潰瘍 (DFU) の症例数の増加と、この疾患を治療するための生物学的製剤の技術的進歩により高まっています。さらに、このような感染症にかかりやすい高齢者人口の増加が市場の成長に大きく貢献しています。例えば、2024年12月にJournal of Diabetes Researchに掲載された研究では、DFU患者のほとんどが50歳から59歳の年齢層であり、死亡の大部分は70歳から79歳の年齢層で発生していることがわかりました。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Third Party Perspective
1.3.5. Primary research
1.3.6. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Data Sources
1.8. List of Primary Sources
1.9. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Diabetic Foot Ulcer Biologics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of diabetic foot ulcer
3.2.1.2. Technological advancements in biologics
3.2.1.3. Rising geriatric population
3.2.2. Market restraint analysis
3.2.2.1. High cost of biologics products
3.2.3. Market opportunity analysis
3.2.3.1. Rising distribution agreement for biologics
3.2.3.2. Growing number of clinical trials
3.2.3.3. Expansion of manufacturing and distribution facilities
3.2.3.4. Expansion in emerging markets
3.2.4. Market challenge analysis
3.2.4.1. Intense Competition
3.3. Diabetic Foot Ulcer Biologics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
Chapter 4. Diabetic Foot Ulcer Biologics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
4.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.3.1. Skin Substitutes
4.3.1.1. Skin-Substitutes market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.2. Biological
4.3.1.2.1. Biological market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.3. Synthetic
4.3.1.3.1. Synthetic market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.4. Bio-Synthetic
4.3.1.4.1. Bio-Synthetic market estimates and forecast 2018 to 2030 (USD Million)
4.3.2. Growth Factors
4.3.2.1. Growth factors market estimates and forecast 2018 to 2030 (USD Million)
4.3.3. Tissue-Engineered Products
4.3.3.1. Tissue-engineered products market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Diabetic Foot Ulcer Biologics Market: Indication Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
5.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
5.3.1. Neuro-ischemic Ulcers
5.3.1.1. Neuro-ischemic ulcers market estimates and forecast 2018 to 2030 (USD Million)
5.3.2. Neuropathic Diabetic Foot Ulcer
5.3.2.1. Neuropathic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)
5.3.3. Ischemic Diabetic Foot Ulcer
5.3.3.1. Ischemic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Diabetic Foot Ulcer Biologics Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
6.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
6.5. Clinics
6.5.1. Clinics market estimates and forecast 2018 to 2030 (USD Million)
6.6. Ambulatory Surgical Centers (ASCs)
6.6.1. Ambulatory Surgical Centers (ASCs) market estimates and forecast 2018 to 2030 (USD Million)
6.7. Long-Term Care Settings
6.7.1. Long-term care settings market estimates and forecast 2018 to 2030 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Diabetic Foot Ulcer Biologics Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Competitive scenario
7.3.2.3. Regulatory framework
7.3.2.4. Reimbursement scenario
7.3.2.5. U.S. market estimates and forecasts, 2018 - 2030
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Competitive scenario
7.3.3.3. Regulatory framework
7.3.3.4. Reimbursement scenario
7.3.3.5. Canada market estimates and forecasts, 2018 - 2030
7.3.4. Mexico
7.3.4.1. Key country dynamics
7.3.4.2. Competitive scenario
7.3.4.3. Regulatory framework
7.3.4.4. Reimbursement scenario
7.3.4.5. Mexico market estimates and forecasts, 2018 - 2030
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Competitive scenario
7.4.1.3. Regulatory framework
7.4.1.4. Reimbursement scenario
7.4.1.5. UK market estimates and forecasts, 2018 - 2030
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory framework
7.4.2.4. Reimbursement scenario
7.4.2.5. Germany market estimates and forecasts, 2018 - 2030
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory framework
7.4.3.4. Reimbursement scenario
7.4.3.5. France market estimates and forecasts, 2018 - 2030
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory framework
7.4.4.4. Reimbursement scenario
7.4.4.5. Italy market estimates and forecasts, 2018 - 2030
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Regulatory framework
7.4.5.4. Reimbursement scenario
7.4.5.5. Spain market estimates and forecasts, 2018 - 2030
7.4.6. Denmark
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Regulatory framework
7.4.6.4. Reimbursement scenario
7.4.6.5. Denmark market estimates and forecasts, 2018 - 2030
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Competitive scenario
7.4.7.3. Regulatory framework
7.4.7.4. Reimbursement scenario
7.4.7.5. Sweden market estimates and forecasts, 2018 - 2030
7.4.8. Norway
7.4.8.1. Key country dynamics
7.4.8.2. Competitive scenario
7.4.8.3. Regulatory framework
7.4.8.4. Reimbursement scenario
7.4.8.5. Norway market estimates and forecasts, 2018 - 2030
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Competitive scenario
7.5.1.3. Regulatory framework
7.5.1.4. Reimbursement scenario
7.5.1.5. Japan market estimates and forecasts, 2018 - 2030
7.5.2. India
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Regulatory framework
7.5.2.4. Reimbursement scenario
7.5.2.5. India market estimates and forecasts, 2018 - 2030
7.5.3. China
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Regulatory framework
7.5.3.4. Reimbursement scenario
7.5.3.5. China market estimates and forecasts, 2018 - 2030
7.5.4. South Korea
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Regulatory framework
7.5.4.4. Reimbursement scenario
7.5.4.5. South Korea market estimates and forecasts, 2018 - 2030
7.5.5. Australia
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Regulatory framework
7.5.5.4. Reimbursement scenario
7.5.5.5. Australia market estimates and forecasts, 2018 - 2030
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Regulatory framework
7.5.6.4. Reimbursement scenario
7.5.6.5. Thailand market estimates and forecasts, 2018 - 2030
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Competitive scenario
7.6.1.3. Regulatory framework
7.6.1.4. Reimbursement scenario
7.6.1.5. Brazil market estimates and forecasts, 2018 - 2030
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Regulatory framework
7.6.2.4. Reimbursement scenario
7.6.2.5. Argentina market estimates and forecasts, 2018 - 2030
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Competitive scenario
7.7.1.3. Regulatory framework
7.7.1.4. Reimbursement scenario
7.7.1.5. South Africa market estimates and forecasts, 2018 - 2030
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. Reimbursement scenario
7.7.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Reimbursement scenario
7.7.3.5. UAE market estimates and forecasts, 2018 - 2030
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Competitive scenario
7.7.4.3. Regulatory framework
7.7.4.4. Reimbursement scenario
7.7.4.5. Kuwait market estimates and forecasts, 2018 - 2030
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Organogenesis Holdings Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Tissue Regenix
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. BioTissue
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Integra LifeSciences
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. MIMEDX Group, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Convatec Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Coloplast Group (Kerecis)
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Biocomposites
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Smith+Nephew, Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Stedical Scientific, Inc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Zimmer Biomet
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. GUNZE LIMITED
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives
8.4. Heat Map Analysis/ Company Market Position Analysis
8.5. Estimated Company Market Share Analysis, 2024
8.6. List of Other Key Market Players
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. North America diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
Table 4. North America diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 5. North America diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 6. North America diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 7. U.S. diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 8. U.S. diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 9. U.S. diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 10. Canada diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 11. Canada diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 12. Canada diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 13. Mexico diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 14. Mexico diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 15. Mexico diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 16. Europe diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
Table 17. Europe diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 18. Europe diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 19. Europe diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 20. UK diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 21. UK diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 22. UK diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 23. Germany diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 24. Germany diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 25. Germany diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 26. France diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 27. France diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 28. France diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 29. Italy diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 30. Italy diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 31. Italy diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 32. Spain diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 33. Spain diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 34. Spain diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 35. Denmark diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 36. Denmark diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 37. Denmark diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 38. Sweden diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 39. Sweden diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 40. Sweden diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 41. Norway diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 42. Norway diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 43. Norway diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 44. Asia Pacific diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
Table 45. Asia Pacific diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 46. Asia Pacific diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 47. Asia Pacific diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 48. China diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 49. China diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 50. China diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 51. Japan diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 52. Japan diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 53. Japan diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 54. India diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 55. India diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 56. India diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 57. South Korea diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 58. South Korea diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 59. South Korea diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 60. Australia diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 61. Australia diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 62. Australia diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 63. Thailand diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 64. Thailand diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 65. Thailand diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 66. Latin America diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
Table 67. Latin America diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 68. Latin America diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 69. Latin America diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 70. Brazil diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 71. Brazil diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 72. Brazil diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 73. Mexico diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 74. Mexico diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 75. Mexico diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 76. Argentina diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 77. Argentina diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 78. Argentina diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 79. Middle East & Africa diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
Table 80. Middle East & Africa diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 81. Middle East & Africa diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 82. Middle East & Africa diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 83. South Africa diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 84. South Africa diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 85. South Africa diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 86. Saudi Arabia diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 87. Saudi Arabia diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 88. Saudi Arabia diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 89. UAE diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 90. UAE diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 91. UAE diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
Table 92. Kuwait diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
Table 93. Kuwait diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
Table 94. Kuwait diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Diabetic Foot Ulcer Biologics Market, Market Segmentation
Fig. 7 Market Driver Analysis (Current & Future Impact)
Fig. 8 Market Restraint Analysis (Current & Future Impact)
Fig. 9 Market Opportunity Analysis (Current & Future Impact)
Fig. 10 Market Challenge Analysis (Current & Future Impact)
Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 12 Porter’s Five Forces Analysis
Fig. 13 Regional Marketplace: Key Takeaways
Fig. 14 Global Diabetic Foot Ulcer Biologics Market, for Product, 2018 - 2030 (USD Million)
Fig. 15 Global Diabetic Foot Ulcer Biologics Market, for Skin Substitutes, 2018 - 2030 (USD Million)
Fig. 16 Global Diabetic Foot Ulcer Biologics Market, for Biological, 2018 - 2030 (USD Million)
Fig. 17 Global Diabetic Foot Ulcer Biologics Market, for Synthetic, 2018 - 2030 (USD Million)
Fig. 18 Global Diabetic Foot Ulcer Biologics Market, for Bio-Synthetic, 2018 - 2030 (USD Million)
Fig. 19 Global Diabetic Foot Ulcer Biologics Market, for Growth Factors, 2018 - 2030 (USD Million)
Fig. 20 Global Diabetic Foot Ulcer Biologics Market, for Tissue-Engineered Products, 2018 - 2030 (USD Million)
Fig. 21 Global Diabetic Foot Ulcer Biologics Market, for Indication, 2018 - 2030 (USD Million)
Fig. 22 Global Diabetic Foot Ulcer Biologics Market, for Neuro-ischemic Ulcers, 2018 - 2030 (USD Million)
Fig. 23 Global Diabetic Foot Ulcer Biologics Market, for Neuropathic Diabetic Foot Ulcer, 2018 - 2030 (USD Million)
Fig. 24 Global Diabetic Foot Ulcer Biologics Market, for Ischemic Diabetic Foot Ulcer, 2018 - 2030 (USD Million)
Fig. 25 Global Diabetic Foot Ulcer Biologics Market, for End Use, 2018 - 2030 (USD Million)
Fig. 26 Global Diabetic Foot Ulcer Biologics Market, for Hospitals, 2018 - 2030 (USD Million)
Fig. 27 Global Diabetic Foot Ulcer Biologics Market, for Clinics, 2018 - 2030 (USD Million)
Fig. 28 Global Diabetic Foot Ulcer Biologics Market, for Ambulatory Surgical Centers (ASCs), 2018 - 2030 (USD Million)
Fig. 29 Global Diabetic Foot Ulcer Biologics Market, for Long-Term Care Settings, 2018 - 2030 (USD Million)
Fig. 30 Global Diabetic Foot Ulcer Biologics Market, for Others, 2018 - 2030 (USD Million)
Fig. 31 Regional Outlook, 2024 & 2030
Fig. 32 North America Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 33 U.S. Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 34 Canada Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 35 Mexico Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 36 Europe Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 37 Germany Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 38 UK Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 39 France Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 40 Italy Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 41 Spain Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 42 Denmark Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 43 Sweden Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 44 Norway Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 45 Asia Pacific Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 46 Japan Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 47 China Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 48 India Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 49 Australia Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 50 South Korea Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 51 Thailand Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 52 Latin America Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 53 Brazil Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 54 Argentina Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 55 Middle East and Africa Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 56 South Africa Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 58 UAE Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
Fig. 59 Kuwait Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)